The Food and Drug Administration (FDA) has approved Somatuline Depot (lanreotide; Ipsen Biopharmaceuticals) injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ...
The 16-week study (n=115) enrolled patients with histopathologically-confirmed neuroendocrine tumors and a history of carcinoid syndrome who were treatment-naive or stable on another somatostatin ...
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has approved a ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved a ...
Subcutaneous injections are a method of administering medication just under the skin, between the fatty tissue and muscle. It allows medication to be absorbed slowly over a longer period of time.
Please provide your email address to receive an email when new articles are posted on . The FDA has approved a prior approval supplement application for the extended dosing interval of lanreotide ...
A subcutaneous injection, or shot, enters the fatty tissues just beneath the skin. It is shallower than an injection into muscle tissue. Healthcare professionals often use subcutaneous injections for ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results